Market revenue in 2023 | USD 623.4 million |
Market revenue in 2030 | USD 1,897.6 million |
Growth rate | 17.2% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.3% in 2023. Horizon Databook has segmented the China circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
China is expected to grow at a moderate to slow rate over the forecast period. Increase in healthcare expenditure for pharmaceuticals and government initiatives that encourage generic players to enter the regional market are among some of the factors anticipated to drive market growth.
In June 2019, the Chinese authorities introduced an initiative by publishing a list of 34 off-patent or nearing patent expiration products. Moreover, generic players are encouraged to manufacture products under drug regulator’s priority review pathway, which is generally granted to innovative drugs.
Furthermore, the government supports R&D of generics to enhance the quality and efficacy of products. In April 2018, the State Council passed a circular on Opinions Concerning Reforms of Policies to Improve the Supply and Utilization of Generics, which may have a positive impact on the market dynamics of generic manufacturers.
Horizon Databook provides a detailed overview of country-level data and insights on the China circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into China circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account